Scarica l'app Stockscreener
248.18
2.02%
5.0371
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie to Host Second-Quarter 2026 Earnings Conference Call - Yahoo Finance
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value? - The Motley Fool
Rx Rundown: Merck KGaA, AbbVie, Sangamo Therapeutics and more - Medical Marketing and Media
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (DUS:4AB0) - TradingView
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix? - Yahoo Finance
Enterprise value to EBITDA forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
A Look at AbbVie Inc (ABBV) After 3.5% Gain -- GF Value $211.36 vs Price $243.14 - GuruFocus
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Price to book forward of AbbVie, Inc. – TURQUOISE:4ABD - TradingView
Enterprise value to EBIT forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie Inc Stock (ABBV) Moved Up by 3.22% on Jun 25: Drivers Behind the Movement - TradingKey
Is AbbVie a Buy After Its Purchase of Apogee? - AOL.com
AbbVie to acquire Apogee Therapeutics in $10.9 billion immunology deal - DOTmed
Pharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bet - Pharmaceutical Commerce
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook - Yahoo Finance
The Number That Could Test AbbVie Stock - Trefis
AbbVie's Big Immunology Acquisition - Forbes
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years - Benzinga
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis - Zacks Investment Research
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $260 to $298 - Moomoo
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal - Yahoo Finance
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition - Investing.com
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com Canada
PRESCRIPTION DRUGS—W.D. Wash.: Novartis, AbbVie, PhRMA denied preliminary relief in challenge to Washington State 340B delivery law - VitalLaw.com
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors. - Yahoo Finance
ABBV Reiterated by Piper Sandler -- Price Target Maintained at $298 - GuruFocus
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds - PR Newswire
CCORF Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $273 - Moomoo
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout - Yahoo Finance
Abbvie stock holds at Market Perform as Bernstein eyes Apogee deal - Investing.com Canada
ABBV Introduces Boey for Glabellar Lines Following Health Canada Approval - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $234 to $298 - Moomoo
AbbVie receives European approval for age three patients - grafa.com
Years of Rewards: $61 Bil From AbbVie Stock - Trefis
Canaccord raises Abbvie stock price target on acquisition potential - Investing.com
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) - Yahoo Finance
Canaccord raises Abbvie stock price target on acquisition potential By Investing.com - Investing.com Canada
Should You Buy Or Sell AbbVie Stock At $230? - Yahoo Finance
Possible Bearish Signals With AbbVie Insiders Disposing Stock - Moomoo
AbbVie Stock Rose 6% After Its $11 Billion Apogee Deal: What a $347 Target Means for Investors - TIKR.com
Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com
Canada clears Boey, a fast-acting neurotoxin that fades in 2-3 weeks - Stock Titan
AbbVie receives European approval for age six patients - grafa.com
AbbVie (ABBV) Gains European Approval for Skyrizi in Younger Pat - GuruFocus
ABBV Receives EU Approval for Maviret Treatment - GuruFocus
AbbVie (ABBV) Secures EU Approval for Skyrizi in Pediatric Psori - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace
AbbVie (ABBV) Gains European Approval for SKYRIZI in Pediatric P - GuruFocus
AbbVie Announces European Commission Approval of MAVIRET® for People with Acute Hepatitis C Virus Infection - Investing News Network
AbbVie Inc. (ABBV) Apogee Therapeutics, Inc.M&A CallSlideshow (NYSE:ABBV) 2026-06-23 - Seeking Alpha
AbbVie Announces European Commission Approval of SKYRIZI® for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis - Investing News Network
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET - Business Wire
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection - Yahoo Finance
UBS downgrades Apogee Therapeutics stock rating on AbbVie deal - Investing.com
Key facts: AbbVie to Buy Apogee for $10.9B; Lead Drug Ph3 Expected - TradingView
AbbVie’s SKYRIZI cleared for kids with plaque psoriasis in Europe - Stock Titan
AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge - MedCity News
Wells Fargo Maintains Overweight on AbbVie (ABBV), Sees Value in Apogee Acquisition - Insider Monkey
Why AbbVie Stock Jumped Today - The Motley Fool
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio - Investing News Network
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger - Insider Monkey
Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee - NAI500
2.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):